Yongqian Shu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongqian Shu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Xiaoqin Li
Department of Medical Oncology, Affiliated Hospital of Jiangsu University, Jiefang Road, Zhenjiang 212001, China
2 shared publications- Aihua Yao
Hepatobiliary Center, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
1 shared publication Bo Shen
Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Baiziting Road, Nanjing 210009, China
1 shared publicationC. Li
Hepatobiliary Center, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
1 shared publicationDan Li
The Cancer Therapy Center, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
1 shared publicationDeqiang Wang
Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road, Nanjing 210029, China; Department of Medical Oncology, Affiliated Hospital of Jiangsu University, Jiefang Road, Zhenjiang 212001, China
1 shared publication
Latest Publications
- Open Access
- 5 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (27) , e38459
Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials
Background: Maintenance therapy could significantly improve the prognosis of patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Anlotinib is effective, tolerable, and convenient in administration as a third-line treatment for NSCLC. This study aimed to evaluate the efficacy and safety of maintenance therapy with anlotinib after platinum-based induction chemotherapy for patients with advanced NSCLC. Methods: This pooled analysis of 2 multicenter, open-label, single-arm, phase 2 clinical trials (ALTER-L014 and ALTER-L011) enrolled patients with locally advanced or metastatic NSCLC and without known sensitive mutations in China between September 2018 and January 2021. The primary outcome was progression-free survival. The secondary outcomes were objective response rate, disease control rate, overall survival, and safety. Results: The data of 23 patients were pooled, with 15 from ALTER-L014 and 8 from ALTER-L011. At the cutoff date of June 13, 2021, the median progression-free survival since the start of maintenance therapy was 5.95 (95% confidence interval, 4.30–8.80) months. Nineteen patients had stable disease, 1 had a partial response and 3 had progressive disease. The objective response rate was 4.35%, while disease control rate was 86.96%. The median overall survival of the patients since the start of maintenance therapy was 18.60 (95% confidence interval, 6.87–22.80) months. The incidence of adverse events of grade ≥ 3 was 21.7%. Conclusion: Anlotinib might offer a new option for maintenance treatment in patients with locally advanced or metastatic NSCLC without known sensitive mutations after standard first-line platinum-based chemotherapy.
- 5 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (27) , e38459
Open AccessMaintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials
Background: Maintenance therapy could significantly improve the prognosis of patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Anlotinib is effective, tolerable, and convenient in administration as a third-line treatment for NSCLC. This study aimed to evaluate the efficacy and safety of maintenance therapy with anlotinib after platinum-based induction chemotherapy for patients with advanced NSCLC. Methods: This pooled analysis of 2 multicenter, open-label, single-arm, phase 2 clinical trials (ALTER-L014 and ALTER-L011) enrolled patients with locally advanced or metastatic NSCLC and without known sensitive mutations in China between September 2018 and January 2021. The primary outcome was progression-free survival. The secondary outcomes were objective response rate, disease control rate, overall survival, and safety. Results: The data of 23 patients were pooled, with 15 from ALTER-L014 and 8 from ALTER-L011. At the cutoff date of June 13, 2021, the median progression-free survival since the start of maintenance therapy was 5.95 (95% confidence interval, 4.30–8.80) months. Nineteen patients had stable disease, 1 had a partial response and 3 had progressive disease. The objective response rate was 4.35%, while disease control rate was 86.96%. The median overall survival of the patients since the start of maintenance therapy was 18.60 (95% confidence interval, 6.87–22.80) months. The incidence of adverse events of grade ≥ 3 was 21.7%. Conclusion: Anlotinib might offer a new option for maintenance treatment in patients with locally advanced or metastatic NSCLC without known sensitive mutations after standard first-line platinum-based chemotherapy.
- 1 November 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S1305
170P Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- 1 November 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S1305
170P Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)